Skip to main content
Geoffrey Uy, MD, Oncology, Saint Louis, MO, Siteman Cancer Center

GeoffreyLimUyMD

Oncology Saint Louis, MO

Hematologic Oncology

Professor of Medicine, Washington University School of Medicine

Overview of Dr. Uy

Dr. Geoffrey Uy, MD is an oncologist in Saint Louis, Missouri. He is currently licensed to practice medicine in Missouri and Illinois. He is affiliated with Siteman Cancer Center and Barnes-Jewish Hospital.

Education & Training

  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineFellowship, Hematology and Medical Oncology, 2003 - 2007
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineResidency, Internal Medicine, 2001 - 2003
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 2001

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2020 - 2023
  • MO State Medical License
    MO State Medical License 2002 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
    Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
  • Single Institution Experience with G-CSF Mobilized T-cell Replete Haploidentical Hematopoietic Cell Transplantation  
    M A Schroeder, R Romee, J F DiPersio, T A Fehniger, F Gao, G L Uy, C N Abboud, P Westervelt, R Vij, Nature

Abstracts/Posters

  • A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with R...
    Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death
    Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
    Geoffrey L. Uy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Alliance A041701 - a Randomized Phase 2/3 Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia (AML) Receiving Int... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy
    GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive ChemotherapyMay 30th, 2018
  • MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting
    MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual MeetingDecember 11th, 2019
  • OncLive® to Host State of the Science Summit™ on Treatment of Hematologic Malignancies
    OncLive® to Host State of the Science Summit™ on Treatment of Hematologic MalignanciesNovember 5th, 2018
  • Join now to see all

Grant Support

  • Targeting Leukemia Stromal Interactions In AMLNational Cancer Institute2009–2011

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem Blue Access Choice PPO
    Anthem Blue Access PPO
    BCBS Blue Card PPO
    BCBS California PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Coventry Health Care PPO Platinum
    Coventry Missouri - HMO/POS
    First Health PPO
    Great West PPO
    HealthLink PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment